# US 2019/0167735 A1 · Use of gram negative species to treat atopic dermatitis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167735 A1
- Document ID: US20190167735A1
- Status: Published application
- Kind: A1
- Application number: 16/271,577
- Filed: 2019-02-08
- Published: 2019-06-06
- Earliest claimed: 2016-04-19
- Assignees: U.S. of America, represented by the Secretary, Department of Health and Human Services.
- Applicants: The U.S. of America, as Represented by the Secretary, Department of Health and Human Services
- Inventors: Ian Antheni MYLES; Sandip K. DATTA
- Web page: https://patentgrep.com/patent/US20190167735A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61P 17/04: Antipruritics
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Pharmaceutical compositions are disclosed that includes a therapeutically effective amount of a purified viable Gram negative bacteria and a pharmaceutically acceptable carrier. The pharmaceutical compositions are formulated for topical administration. Methods of treating atopic dermatitis using these pharmaceutical compositions are also disclosed.

## Claims

### Claim 1

A kit for treatment of atopic dermatitis, comprising:
a) a first container comprising a pharmaceutical composition, wherein the pharmaceutical composition comprises:
a therapeutically effective amount of at least one strain of Roseomonas mucosa, wherein said strain of Roseomonas mucosa comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3; and
b) instructions for applying the therapeutically effective amount of the pharmaceutical composition to skin of a subject in need thereof.

### Claim 2 (depends on 1)

The kit of claim 1, wherein the first container further comprises a first pharmaceutically acceptable carrier.

### Claim 3 (depends on 2)

The kit of claim 2, wherein the first pharmaceutically acceptable carrier comprises sucrose.

### Claim 4 (depends on 3)

The kit of claim 3, wherein the first pharmaceutically acceptable carrier is sucrose.

### Claim 5 (depends on 1)

The kit of claim 1, wherein pharmaceutical composition is lyophilized.

### Claim 6 (depends on 1)

The kit of claim 1, further comprising a second container comprising a second pharmaceutically acceptable carrier.

### Claim 7 (depends on 6)

The kit of claim 6, wherein the second pharmaceutically acceptable carrier is in a topical dosage form of a cream, gel, foam, ointment, or liquid.

### Claim 8 (depends on 7)

The kit of claim 7, wherein the topical dosage form is liquid.

### Claim 9 (depends on 8)

The kit of claim 8, wherein the second pharmaceutically acceptable carrier is water.

### Claim 10 (depends on 1)

The kit of claim 1, wherein said strain of Roseomonas mucosa is isolated from a subject that does not have atopic dermatitis.

### Claim 11 (depends on 1)

The kit of claim 1, wherein the subject is an adult.

### Claim 12 (depends on 1)

The kit of claim 1, wherein the subject is a child.

### Claim 13 (depends on 1)

The kit of claim 1, wherein the subject is an infant.

### Claim 14 (depends on 1)

The kit of claim 1, wherein said strain of Roseomonas mucosa comprises the nucleic acid sequence of SEQ ID NO: 1.

### Claim 15 (depends on 1)

The kit of claim 1, wherein said strain of Roseomonas mucosa comprises the nucleic acid sequence of SEQ ID NO: 2.

### Claim 16 (depends on 1)

The kit of claim 1, wherein said strain of Roseomonas mucosa comprises the nucleic acid sequence of SEQ ID NO: 3.

### Claim 17 (depends on 1)

The kit of claim 1, wherein the at least one strain of Roseomonas mucosa comprises a mixture of three strains of Roseomonas mucosa, and wherein each of said strains comprises one of the nucleic acid sequences selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3.

### Claim 18 (depends on 1)

The kit of claim 1, wherein the at least one strain of Roseomonas mucosa is present in the pharmaceutical composition in a total amount of 104 to 1012 colony forming units.